In CVD conditions such as diabetes and atherosclerosis, increased arginase activity can lead to endothelial dysfunction by competing with eNOS for the bioavailability of l-arginine, thus impairing NO production and leading to endothelial dysfunction. Here, NOS3 is linked to endothelial dysfunction.